And whether you know...
The description is actual on 30.10.2015
- Latin name: Drotaverine hydrochloride
- ATH code: A03AD02
- Active ingredient: Drotaverinum (Drotaverine)
- Producer: JSC Dalkhimfarm, JSC Biokhimik, CJSC Vifitekh, CJSC PFK Obnovleniye, JSC Valenta Farmatsevtika, JSC Biosintez, JSC Dalkhimfarm, JSC Organika, JSC Moskhimfarmpreparaty im. N. A. Semashko, CJSC Farmproyekt and so forth (Russia)
1 tablet includes 40 mg of Drotaverinum of a hydrochloride – active ingredient.
1 ml of injection solution includes 20 mg of Drotaverinum of a hydrochloride – active ingredient.
Depending on the producer the structure of additional components of drug can differ, but generally for tablets it: monohydrate of lactose, povidone, talc, potato starch, krospovidon and magnesium stearate, and for injection solution: ethanol, disodium sulfite and water for infection.
The main forms of release of Drotaverinum of the Hydrochloride are: tablets and injection solution, with various quantity of units in secondary packaging.
Pharmacodynamics and pharmacokinetics
Derivative isoquinoline – Drotaverinum – is a myotropic spasmolysant which on the chemical structure and pharmacological action is similar to the Papaverine, but is characterized by more long and expressed efficiency. Drotaverinum is capable to reduce inflow of calcium ions to cells of smooth muscles, by means of oppression of phosphodiesterase and cumulation of intracellular tsAMF, to lower a peristaltics of intestines and a muscle tone of internals, and also to expand vessels of circulatory system. Drug does not get into TsNS and does not exert impact on a vegetative (visceral) nervous system.
Because of the immediate effect on smooth muscle fabrics use of Drotaverinum as spasmolysant is shown in cases when use of M — holinoblokator contraindicated (a prostate hyperplasia, closed-angle glaucoma).
Reception of Drotaverinum peroral (inside) leads to its quite fast absorption in a gastrointestinal tract, the period of semi-absorption is equal to about 12 minutes. Drug is characterized by 100% bioavailability, hypodispersion in fabrics and high penetration into cells of smooth muscles. Serumal Cmax is observed 120 minutes later. Linkng with plasma proteins happens for 95-98%. Drotaverinum does not get through a blood-brain barrier. It is removed mainly with urine and in smaller quantity with bile.
Indications to use
Use of Drotaverinum of the Hydrochloride is shown for prevention and therapy of the pain syndrome associated with spasms of smooth muscle fabrics at the following painful states: gastroduodenit, cholelithiasis, cholecystitis, a postcholecystectomy syndrome, a peptic ulcer, a spastic colitis, algodismenorreya, a nephrolithiasis.
One more scope of Drotaverinum is carrying out some tool researches (including the cholecystography).
Use of Drotaverinum of the Hydrochloride is absolutely forbidden at:
- cardiogenic shock;
- personal hypersensitivity to Drotaverinum or other components of HP;
- the expressed insufficiency of hepatic/renal and cordial function;
- arterial hypotension;
- II-III degrees of an atrioventricular block;
- aged till 2 years.
With precaution it is necessary to appoint drug at:
- feeding by a breast;
- the expressed atherosclerosis;
- to closed-angle glaucoma;
- prostate hyperplasia.
In certain cases at use of Drotaverinum observed:
- feeling of heat;
- lowering of the ABP;
- skin allergic manifestations.
In a case in/in introductions are possible:
- atrioventricular block;
- breath suppression;
- nausea/vomiting (at fast introduction).
The instruction on Drotaverinum the Hydrochloride provides a possibility of use of drug orally – for tablets and in/in, in oil and p / to – for injection solution.
The single dose of Drotaverinum of a hydrochloride for adult patients, both in tablets, and in injections, varies within 40-80 mg, with a frequency of use of 2-3 times a day.
Aged from 2 years appoint one-time 10-20 mg of drug; from 6 to 12 years on 20 mg, with a frequency of use of 1-2 times of 24 hours.
In case of need the fastest effect are possible in/in a drug injection, at the same time 2-4 ml of ampullary Drotaverinum of a hydrochloride part in 10-20 ml of solution of sodium chloride (0,9%) or Dextrosums (5%) and enter slowly.
The application instruction assumes use of injection solution for incidental or short treatment. In need of carrying out long therapy of the patient transfer to the tableted drug form.
At overdose by Drotaverinum observed: disturbances of atrioventricular conductivity, reduction of excitability of a myocardium, paralysis of the center of breath and cardiac standstill.
Treatment is carried out according to observed symptomatology of overdose and its weight.
Parallel use with the Levodopa can reduce its protivoparkinsonichesky efficiency.
At the combined use with Prokainamid and Quinidine, anti-hypertensive drugs, tricyclic antidepressants their hypotensive action increases.
The combined use with Phenobarbital leads to increase in expressiveness of spasmolytic efficiency of Drotaverinum of a hydrochloride.
Terms of sale
Peroral and injection forms of drug belong to the prescription list.
The maximum temperature of storage of both dosage forms makes 25 °C.
Period of validity
Depending on the producer – 2-3 years.
At use of Drotaverinum of a hydrochloride it is better to refrain from performance of exact or dangerous works and driving of the car, in particular during the first hours after parenteral administration.
/a class='other-apteks-link link03'>to show still
PAY ATTENTION! Information on drugs on the website is help generalizing, collected from public sources and can form the basis for making decision on use of medicines it is not aware of treatment. Before Drotaverinum medicine use the Hydrochloride surely consult with the attending physician.